| Drug Name |
Anagrelide |
| Drug ID |
BADD_D00139 |
| Description |
Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms.[L14153] It is an oral imidazoquinazoline that was first approved for use in the US in 1997.[A214274] It appears to carry a better response rate than other thrombocythemia treatments (e.g. [busulfan], [hydroxyurea]) and may be better tolerated.[A214274] |
| Indications and Usage |
Anagrelide is indicated for the treatment of thrombocythemia, secondary to malignant neoplasms, to reduce platelet count and the associated risk of thrombosis. It is also beneficial in the amelioration of thrombocythemia symptoms including thrombo-hemorrhagic events.[L14153] |
| Marketing Status |
approved |
| ATC Code |
L01XX35 |
| DrugBank ID |
DB00261
|
| KEGG ID |
D07455
|
| MeSH ID |
C021139
|
| PubChem ID |
135409400
|
| TTD Drug ID |
D0D1HW
|
| NDC Product Code |
13668-462; 13668-453 |
| UNII |
K9X45X0051
|
| Synonyms |
anagrelide | Agrylin | BL 4162A | Agrelin | anagrelide hydrochloride | imidazo(2,1-b)quinazolin-2(3H)-one, 6,7-dichloro-1,5-dihydro-, monohydrochloride | 6,7-dichloro-1,5-dihydroimidazo(2,1-b)quinazolin-2(3H)-one hydrochloride |
